Science
TECNO POP 9 With India’s First MediaTek G50 Hits Shelves on 26th November
New Delhi, India: Monday, November 25, 2024 4:53PM IST (11:23AM GMT Users can purchase the TECNO POP 9 at an...
BANGALORE TECH SUMMIT-2024
Bengaluru, November 19 (Karnataka News): Chief Minister Siddaramaiah said that the Bangalore Tech Summit 2024 program is a unique platform...
Assam’s Semiconductor Plant: A Game-Changer for India’s Semiconductor Ecosystem
17 NOV 2024 5:30PM by PIB Delhi India’s ambitious strides in the semiconductor industry are best exemplified by the development...
CAQM invokes Stage-IV of the GRAP in the entire Delhi-NCR w.e.f. 08:00 AM of 18.11.2024 (tomorrow) in addition to all actions under Stage I, II and III to prevent further deterioration of air quality in the region
The decision is taken in wake of Delhi’s daily average AQI clocked 441 today at 4PM, as per the Daily...
Unisys Opens Registration for Its 16th Annual Unisys Innovation Program
The program's next cycle will focus on emerging technologies such as artificial intelligence (AI), quantum computing, and the internet of...
SPARSH Hospitals Launches India’s First Advanced On-Site 3D Printing Lab
* SPARSH Hospitals: Pioneering New Technologies in Orthopedics and Personalised Healthcare * Adaption and Integration of Robotics and 3D Printing...
Central Consumer Protection Authority Issues Guidelines for ‘Prevention and Regulation of Greenwashing and Misleading Environmental Claims’
15 OCT 2024 3:00PM by PIB Delhi In exercise of the mandate to regulate matters relating to misleading advertisements which...
Karnataka Aims to Be the Gaming and Animation Capital of the Asia: Priyank Kharge at IGC 2024
Tuesday, Oct 15, 2024 17:10:31 New Delhi India (NewsVoir) During a special address at the second edition of...
Vespa.ai Announces Support for ColPali in Retrieval Augmented Generation (RAG)
Integration simplifies and enhances information retrieval from complex, visually rich documents. TRONDHEIM, Norway: Friday, October 11, 2024 10:16AM IST (4:46AM...
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Approval is based on Phase III INAVO120 results, showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-free survival compared with...
Recent News
